4D Molecular Therapeutics (FDMT) - Guggenheim 3rd Annual Healthcare Innovation Conference - 4D MOLECULAR THERAPEUTICS INC

Financial Performance:

• As of Q2, the company holds over $430 million in cash and cash equivalents.
• Current cash runway is projected to extend into the second half of 2028, excluding anticipated commercial spending committed post-Phase 3 data readouts.
• No specific revenue, earnings, or debt figures were disclosed as the company remains in the clinical development stage prior to commercialization.

Guidance and Future Outlook:

• Top-line data for the "Forefront One" North American Phase 3 trial is expected in Q2 2027.
• Top-line data for the global "Forefront Two" Phase 3 trial is projected for the second half of 2027.
• The company aims to establish a new treatment paradigm for wet AMD, positioning its lead asset as a "backbone therapy" for lifelong disease control from a single dose.
• Future commercialization strategy relies on a familiar intravitreal injection model compatible with existing retina clinic workflows and standard "buy-and-bill" reimbursement.

Business Segments and Product Lines:

• Lead Asset (4D150): A genetic medicine designed to deliver aflibercept via an R100 capsid vector for targeted retinal delivery.
• Current Pipeline: Two Phase 3 programs (Forefront One and Two) targeting wet AMD in patients recently diagnosed or previously treated.
• New Initiatives: A clinical trial for Diabetic Macular Edema (DME) commenced approximately two months prior to the call.
• Technology: Proprietary R100 capsid enables low-dose, intravitreal delivery to retinal cells, differentiating it from sub-retinal surgical approaches of competitors.

Market and Competitive Landscape:

• Market Size: The global anti-VEGF category for wet AMD is valued at approximately $16 billion with steady growth.
• Competitive Positioning: Differentiates from standard care (anti-VEGF bolus injections like Eylea, Vabysmo) by offering continuous disease control rather than episodic treatment, addressing the "continuous control gap" caused by patient non-adherence to frequent injection schedules.
• Patient Volume: Initial launch focus is anticipated on patients with higher disease burden (motivated for alternatives), with plans to broaden to moderate/low burden patients once real-world safety and reimbursement are established.
• Clinical Advantage: Early Phase 1-2 data showed an 87% reduction in treatment burden (average 1.66 supplemental injections vs. 12 with standard of care) over two years in recently diagnosed patients.

Risks and Challenges:

• Clinical Risk: Potential for catastrophic vision loss in the placebo arm or adverse events unrelated to the drug could derail trial results.
• Trial Design Mitigation: Protocols include strict retreatment criteria to protect primary endpoints (vision preservation) by intervening early, even if it slightly impacts the treatment burden reduction metric.
• Reimbursement & Adoption: Success depends on payer acceptance of a high upfront cost for a single-dose therapy and physician confidence in the long-term safety profile.
• Safety: While current data shows favorable safety (no serious AEs like vasculitis or endophthalmitis), long-term safety remains to be confirmed with full Phase 3 data.

Management Commentary and Tone:

• Tone: Confident and forward-looking; management expresses high enthusiasm for the "backbone therapy" concept and the potential to redefine standard of care.
• Strategic Focus: Emphasis is placed on continuous VEGF suppression to prevent the "pulsating" fluid oscillations associated with bolus therapies, which may lead to long-term anatomical damage.
• Operational Confidence: Management highlighted a "world-class" clinical operations team and early enrollment success (completing Forefront One enrollment four months ahead of schedule).

Analyst Questions and Answers:

• Ideal Patient Profile: Management indicated that while high-burden patients will drive initial volume, the broadest adoption will target the majority of the patient pool for continuous control once safety/reimbursement are proven.
• Mechanism of Action: Clarified that aflibercept is produced intracellularly in retinal cells, making vitreous concentration measurement difficult; the value proposition relies on continuous local production rather than incremental durability weeks added by competitors.
• Trial Endpoints: Confirmed that retreatment criteria are prioritized to secure primary endpoint success (vision preservation), even if it slightly reduces the calculated treatment burden reduction percentage.
• DME Opportunity: Confirmed the initiation of a trial for Diabetic Macular Edema, viewing the modality as applicable to diabetic eye disease broadly.

Other Key Points:

• The company is a 13-year-old genetic medicine firm headquartered in the Bay Area, leveraging Nobel Prize-winning directed evolution technology from Berkeley.
• Phase 1-2 PRISM study results demonstrated that 66% of recently diagnosed patients remained injection-free at the two-year mark.
• The target product profile includes a single office-based intravitreal injection with a favorable toxicity profile.
• Financial planning involves deferring significant commercial spend until Phase 3 data is available to validate the investment.